ClinicalTrials.Veeva

Menu

Effect of a Uterine Manipulator on the Incidence of Lymphovascular Propagation (LVSI) in Treatment of Endometrial Cancer

F

F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica

Status

Completed

Conditions

Endometrial Cancer
LVSI

Treatments

Procedure: hysterectomy

Study type

Observational

Funder types

Other

Identifiers

NCT05261165
29/2021

Details and patient eligibility

About

We retrospectively analyzed data and compared the impact of intrauterine manipulators on incidence of LVSI in endometrial cancer patients treated at our department.

Full description

Endometrial cancers are among the epithelial malignancies of the lining in the uterine cavity. Standard treatment is surgical, which includes a hysterectomy. The invasion of carcinoma into the lymphovascular space (LVSI - lymphovascular space invasion) is considered a risk factor for the course of the disease Based on the recommended procedures of ESGO-ESTRO-ESP (2020) in the management of endometrial cancer, in the event of significant LVSI positivity, the female patients are included in the upper-medium risk group. A confirmation of LVSI in the preparation is of diagnostic, therapeutic and theoretical importance. During endoscopy approach, we use two types of uterine manipulators, namely the Koh-RUMI manipulator (Cooper Surgical) and the Hegar dilatator along with the McCartney tube (LiNA Medical). We analyzed data and compared the impact of intrauterine manipulators on the incidence of LVSI. In addition, we analyzed tumor grading, invasion and primary histology obtaining methods - curettage or hysteroscopy in correlation to incidence of LVSI.

Enrollment

170 patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

  • endometrioid endometrial cancer,
  • planned primary surgical treatment - hysterectomy,
  • medical condition enabling anesthesia and surgery,
  • pre-surgical clinically-determined affecting of the uterine according to MRI or ultrasound - cT1a or cT1b

Exclusion criteria

  • non-endometrioid type of tumor in definitive histology,
  • stage 2 of a disease and higher,
  • previous chemo or radiotherapy,
  • inability to adequately complete the surgery,
  • uterine perforation during surgery

Trial design

170 participants in 4 patient groups

NonManip
Description:
In the group of female patients operated without a uterine manipulator (NonManip), we included the female patients who were operated by abdominal approach without no need to use a manipulator. These female patients did not meet the predominantly anesthesiological requirements for the tolerance of the Trendelenburg position; respectively, the likelihood of adhesions in the abdominal cavity after previous laparotomy operations was there. Therefore, from a safety point of view, due to the risk of damage to the abdominal organs and the need for extensive adhesiolysis, the primary endoscopic surgery was not performed.
Treatment:
Procedure: hysterectomy
Manip
Description:
The female patients suitable for endoscopic performance to laparoscopic, respectively the robotic hysterectomies, in whom the use of a uterine manipulator (Manip) was planned, were assigned random into two groups.
Treatment:
Procedure: hysterectomy
ManipHe
Description:
Subgroup of Manip group patients, in whome we used the Hegar's dilator as intrauterine manipulator.
Treatment:
Procedure: hysterectomy
ManipKoRu
Description:
Subgroup of Manip group patients, in whome we used the Koh-Rumi device as intrauterine manipulator.
Treatment:
Procedure: hysterectomy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems